You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH):擬500萬歐元認購法國生物醫藥投資基金份額
格隆匯 12-31 18:42

格隆匯12月31日丨藥明康德(603259.SH)公佈,北京時間2019年12月31日,公司全資子企業WuXi Fund I與Jeito S.L.P.簽署Subscription Agreement,約定由WuXi Fund I認繳500萬歐元的A2類投資基金份額,約佔已募集投資基金份額的2.5%。截至公告日,WuXi Fund I尚未實繳出資,後續WuXi Fund I將以自有資金根據認購協議及管理公司的出資要求履行出資義務。

Jeito S.L.P.為一家依據法國法律成立的有限合夥企業,投資基金專注於投資生物醫藥領域早期和成長期的企業。該投資基金預計募集總額不超過5億歐元,WuXi Fund I此次認繳500萬歐元后,投資基金已募集約2億歐元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account